Current Illinois CancerCare Clinical Trials

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin (Temporarily Closed)

Study Number: HN004 (Temporarily Closed)

Study Summary:
This phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as durvalumab or cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation therapy with cetuximab in treating patients with head and neck cancer.

Status: Suspended

Radiation at OSF-Glen Oak and UPH-Methodist

Study Coordinator(s)
  • Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
  • Jessica, 309-243-3615, jjones@illinoiscancercare.com
  • Amanda , 309-243-3663, amullery@illinoiscancercare.com

Study Link

« Search Again